Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORADO-AC – Optimized Doses of Darusentan vs Active Control in Resistant Hypertension
2006-003547-23Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darusentan in resistant hypertension (RH) and hypertension (HTN) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Change in trough sitting systolic blood pressure at Week 14 and Change in trough sitting diastolic blood pressure at Week 14. Started Jul 2007; status: completed.
02
Drugs
darusentan
03
Conditions
resistant hypertension (RH)hypertension (HTN)
Beyond the preview
Go deeper on 2006-003547-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003547-23.